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Background: The aim of this study was to evaluate the concentrations of IgG antibodies against Hsp60 and Hsp65
in sera of patients with ovarian cancer at various stages of clinical progress and for different histopathological types
of disease.
Methods: Serum samples from 149 patients with ovarian carcinoma and 80 healthy women were investigated. The
concentrations of anti-Hsp60 and anti-Hsp65 antibodies were determined using the enzyme-linked immunosorbent
assay technique.
Results: The mean concentrations of anti-Hsp60 and anti-Hsp65 antibodies in the patients with ovarian cancer did
not differ significantly from the mean levels in healthy women. Analysis in relation to the clinical progression stage
showed that the concentrations of these antibodies were higher when the neoplastic process was less advanced
and at early stages significantly higher than in control group. Mean concentrations of both antibodies were not
significantly different in relation to the histological type of the ovarian cancer. The use of chemotherapy as a
primary anticancer treatment did not cause a significant change in the concentration of anti-Hsp60 antibodies, but
the mean level of anti-Hsp65 after this treatment was significantly higher than in control group.
Conclusions: The immunological response to Hsp60/65 is increased in early clinical stages of ovarian cancer and
the level of anti-hsp60/65 antibodies may be then a helpful diagnostic marker. Even antibodies against highly
homologous Hsps may be cross-reactive only partially and differ by some functional properties.
Keywords: Anti-Hsp60 and anti-Hsp65 in ovarian cancerBackground
Ovarian cancer is a frequent cause of death in women in
highly developed countries. This is caused, on one hand,
by too late diagnosis (no early clinical symptoms, no
specific diagnostic markers), and on the other – by
therapeutic problems, particularly at the late stage of
disease. Most patients with advanced ovarian cancer re-
spond well to initial chemotherapy, however, within two
years chemoresistant recurrence follows.
In recent years considerable attention has been paid to
the important role of heat shock proteins (Hsps) in vari-
ous carcinogenesis processes and their participation in
developing resistance to anticancer treatment [1]. Hsps
are excessively expressed in numerous malignant neo-
plasms in humans, including genital cancers. They* Correspondence: piotr@bodzek.pl
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unless otherwise stated.participate in tumour cells proliferation, their differenti-
ation, invasion, metastasis, death and recognition by the
immune system [2,3]. There is evidence that some Hsps,
on one hand, protect cells against apoptosis inducing
factors, like cytokines, ionising radiation or oxidative
stress [4,5], while on the other, excessive expression of
these proteins induced by chronic cell stress may result
in apoptosis inhibition and thus facilitate cell neoplastic
transformation [3,5]. Moreover, chaperone molecules
may then protect transformed neoplastic cells, renaturat-
ing their cell proteins damaged by cytostatic agents used
in anticancer therapy (chemo- or radiotherapy), thus
contributing to increased aggressiveness of neoplasm
and its resistance to treatment (2).
The role of some Hsp in processes of cancerogenesis,
including ovarian cancer, has been considerably well de-
scribed. However, still little is known about a possible role
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cells include mycobacterial Hsp65. In most cells, human
Hsp60 is present constitutively in mitochondria, where it
plays a role in protein assembly, folding and transport [1].
In conditions stressful to a cell, however, not only changes
in its intracellular distribution may occur, but also it may
be expressed on a cell surface or released to the intercellu-
lar space, indicating a possible role of that protein as an
intercellular signalling molecule. It also exhibits immuno-
regulatory properties by inducing a proinflammatory re-
sponse in cells responsible for the innate immune response,
like macrophages, dendritic cells or endothelial cells [6].
Extracellular forms of heat shock proteins, including
Hsp60, also behave as autoantigens and induce host’s B-
and T-cell immune response. Anti-Hsps antibodies can
be found in healthy people and they can be treated as a
part of the natural autoantibodies spectrum [7,8]. Their
increased number can then reflect increased extracellu-
lar expression of shock proteins, caused by cells’ specific
pathologic conditions or their modified activity [7].
Anti-Hsps immunization may also be caused by heterol-
ogous Hsps, e.g. of bacterial origin, as some bacterial
heat shock proteins, like Hsp65, are also surface antigens,
against which antibodies are produced in the immune re-
sponse process [9]. Considering their high inter-species
conservatism, the immune response to heterologous Hsps
may also be a source of cross-reactivity with autoantigens
[9,10]. Increased levels of anti-Hsps antibodies have
already been observed in many diseases, particularly
resulting from autoagression (review in 7). It was also
demonstrated that levels of circulating Hsps and anti-
Hsps antibodies could be useful biomarkers for carcino-
genesis in some tissues, as well as prognosis factors for
survival and susceptibility to treatment [2,7].
Presence of Hsp60 and anti-Hsp60/65 antibodies in
serum of patients with ovarian cancer, however, still re-
mains a new research field, and studies conducted so far
often gave contradictory results. The aim of this study
was, therefore, to evaluate levels of IgG antibodies
against these proteins in serum of patients with ovarian
cancer at different stages of clinical progress and with
various histopathological types of disease.
Material and methods
The study included 149 women with ovarian cancer, hos-
pitalised at the Department of Gynaecology, Obstetrics
and Oncological Gynaecology of Medical University of
Silesia in Bytom. Patients with co-occurring diseases, such
as diabetes, advanced atherosclerosis, hypertension, etc.,
were excluded from the study. The control group con-
sisted of 80 healthy women without any history of cancer.
The blood samples (about 5 ml in volume) were ob-
tained at 8.00 a.m., in the fasted state, from antecubital
veins and they were centrifuged immediately. Thecollected sera had been stored at −70°C until assays
could be performed.
The study protocol was approved by the Local Bioethics
Commission of the Medical University of Silesia in
Katowice. All women included were informed about
the aim of the study and gave their written consent for
participation.
The concentrations of IgG antibodies against Hsp60
(anti-Hsp60) and Hsp65 (anti-Hsp65) in studied serum
samples were determined with the enzyme-linked im-
munosorbent assay (ELISA). The antigens used were re-
combinant human Hsp60 (Enzo Life Sciences Inc.,
Farmingdale, NY) and recombinant Hsp65 from Myco-
bacterium bovis (Calbiochem, San Diego, CA). The ELISA
plates (Maxisorp, Nunc, Denmark) were coated with anti-
gen solution at a concentration 2 mg/ml of 50 mM car-
bonate buffer at pH = 9.6. Studied sera were diluted 400×
(optimal dilution was chosen experimentally) in 0.5% bo-
vine serum albumin in phosphate buffered saline with
Tween-20. Calibration was performed using pooled sera
from about 100 of the healthy blood donors. The 400× di-
lution was assumed to correspond to 100 arbitral units/ml
(AU/ml). A calibration curve consisted of 6 standards,
with levels from 0 to 400 AU/ml. Incubation with studied
sera and standards was conducted for 24 hours at 4°C. For
detection of bound IgG antibodies, a goat anti-human
IgG antibody conjugated with a horseradish peroxidase
(Sigma, St. Louis, MO) was used. A tetramethylbenzidine
solution (Sigma, St. Louis, MO) was used as a substrate
for an enzymatic reaction. Absorbances were read with
the Power Wave XS plate reader (BioTek, Winooski, VT)
at 450 nm (reference wavelength - 630 nm), and results
were processed with the KCJunior software (BioTek,
Winooski, VT). The intra-assay variation was 8%. Deter-
minations were done during one series. The assay sensi-
tivity was about 1 AU.
The obtained results were presented using basic de-
scriptive statistics parameters. The accordance of the
data distribution with the normal distribution was
checked with the Szapiro-Wilk test. The groups were
compared using non-parametric Kolmogorov-Smirnov
and U Mann–Whitney tests, and the test of differences
between structure indications. For study of variability in
the group of patients with ovarian cancer, the Kruskal-
Wallis ANOVA rank test was used. Correlations be-
tween parameters were assessed with the Spearmann’s
rank correlation test. The significance level of p < 0.05
was considered to be statistically significant. Calculations
were conducted with the application STATISTICA for
Windows, version 10.0, from StatSoft Inc. (Tulsa, OK).
Results
The mean age (56.2 ± 10.5 years) of studied women with
ovarian cancer was comparable to the age (52.8 ± 8.2 years)
Table 2 Concentrations of anti-Hsp60 and anti-Hsp65 IgG
antibodies in group of women with ovarian cancer and in
control group
Ovarian cancer Controls
n = 149 n = 80
Anti-Hsp60 (AU/ml) 93,91 ± 127,75 62,42 ± 33,92
(mean ± SD)
% of positive resullts 21,8%* 10%
(> 90 percentile for control group) p = 0.024
Anti-Hsp65 (AU/ml) 97,06 ± 169,95 56,35 ± 35,58
(mean ± SD)
% of positive resullts 20,6%* 10%
(> 90 percentile for control group) p = 0,039
*p < 0.05 in group of women with ovarian cancer compared to control group.
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patients, in 72 patients ovarian cancer was diagnosed for
the first time and they were not treated yet, while 77 pa-
tients already underwent previous anticancer chemother-
apy. The studied group included patients with various
histopathological forms of ovarian cancer and at different
clinical stages. Their detailed characteristics are presented
in Table 1.
The mean concentrations of anti-Hsp60 and anti-
Hsp65 antibodies in the whole group of patients with
ovarian cancer did not differ significantly from the mean
levels of these antibodies in the control group of healthy
women (Table 2). Positive results (values exceeding 90th
percentile for the control group) were observed in 21.8%
patients with ovarian cancer for anti-Hsp60 levels and in
20.6% patients for anti-Hsp65 levels. In both cases, the
percentage of values considered to be positive was sig-
nificantly higher than in the control group.
The analysis depending on the disease clinical stage
(FIGO) showed that the mean levels of anti-Hsp60 and
anti-Hsp65 antibodies were higher when the neoplastic
process was less advanced (Table 3). The mean concen-
trations of both antibodies in patients at the I and the II
clinical stage are significantly higher than in the control
group. The mean levels of both antibodies in patients at
the I stage are significantly higher than at the III and the
IV stages, and mean levels at the II stage are significantly
higher than at the IV stage. The similar observations
were done for the percentages of positive values (details
in Table 3).
The mean levels of anti-Hsp60 and anti-Hsp65 anti-
bodies in the patients with ovarian cancer did not differ
significantly depending on the cancer histopathological
type. In the patients with each histopathological type
they also did not differ significantly from the mean levels
of these antibodies in the control group. The percentagesTable 1 Clinical characteristics of examined women with
ovarian cancer (n = 149)
Clinical data Number of patients (%)
Antineoplastic treatment:
• Untreated so far 72 (48,3)
• After chemotherapy 77 (51,7)
Histopathological type of ovarian cancer:
• Adenocarcinoma papillare serosum 82 (55,0)
• Adenocarcinoma mucinosum 44 (29,6)
• Adenocarcinoma endometrioides 23 (15,4)
Stage of the clinical progresion (by FIGO):
• I 25 (16,8)
• II 31 (20,8)
• III 60 (40,3)
• IV 33 (22,1)of positive values for individual histopathological types of
ovarian cancer were comparable (details in Table 4).
Use of chemotherapy as the primary anticancer treat-
ment in ovarian cancer did not resulted in a significant
change of anti-Hsp60 antibody levels, which were com-
parable to levels observed in the group of untreated pa-
tients and in the control group. The percentages of
positive values in both studied groups of patients were
also comparable (Table 5). In the group of patients after
chemotherapy the mean anti-Hsp65 antibodies concen-
tration was, however, significantly higher than in the
healthy women. The percentages of positive values for
anti-Hsp60 levels in the group of untreated patients, and
for anti-Hsp65 levels in the group of patients after
chemotherapy were also significantly higher than in the
group of healthy women.
In both studied groups of women – the group with
ovarian cancer and the control group of healthy women –
concentrations of studied antibodies were not signifi-
cantly correlated with the age. Levels of anti-Hsp60
and anti-Hsp65 antibodies, however, were positively
correlated with each other, both in the group of patients
with ovarian cancer and in the control group of healthy
women (p = 0.0000, R = 0.35 and p = 0.0000, R = 0.62,
respectively).
Discussion
Ovarian cancer is responsible for as many as 55% of
deaths related to malignant genital neoplasms and 6% of
all deaths caused by malignant neoplasms in women
[11,12]. The prognosis and the long-term survival have
remained stable for a long time, mainly due to inad-
equate diagnostic procedures which usually detect that
cancer only at its advanced stage (only 23% of cases are
detected at the I stage) [12,13]. Also, a delayed diagnosis
is often a consequence of lack of clinical symptoms
which sometimes occur only after appearance of local
and/or distant metastases [14]. Therefore, a key to
Table 3 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending
on stage of clinical disease progression (by FIGO) and in control group
Stage of clinical disease progression (by FIGO) Controls
I II III IV n = 80
n = 25 n = 31 n = 60 n = 33
Anti-Hsp60 (AU/ml) 126,99a)b)e) 97,15c)e) 91,92 70,87 62,42
(mean ± SD) ± 121,90 ± 91,82 ± 160,11 ± 78,70 ± 33,92
% of positive results 46%f) 27%f) 17% 17% 10%
(> 90 percentile for control group) p = 0.0000 p = 0.0213 p = 0.2047 p = 0.2861
Anti-Hsp65 (AU/ml) 190,34a)b)e) 97,80c)e) 89,36d) 44,17 56,35
(mean ± SD) ± 337,27 ± 90,59 ± 137,58 ± 26,07 ± 35,58
% of positive results 46%f) 27%f) 21% 0%f) 10%
(> 90 percentile for control group) p = 0.0000 p = 0.0213 p = 0.0594 p = 0.0493
a)p < 0.05 in group of women with I clinical stage compared to group of women with III clinical stage.
b)p < 0.05 in group of women with I clinical stage compared to group of women with IV clinical stage.
c)p < 0.05 in group of women with II clinical stage compared to group of women with IV clinical stage.
d)p < 0.05 in group of women with III clinical stage compared to group of women with IV clinical stage.
e)p < 0.05 in group of women with I and II clinical stage compared to control group.
f)p < 0.05 in group of women with I, II and IV clinical stage compared to control group.
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prognosis in ovarian cancer is finding methods for early
detection of that neoplasm [13]. Expression of CA125
antigen is limited at early stages of ovarian cancer and
may also be related to non-malignant lesions; therefore,
its prognostic value is only 57% [15]. Determination of
that antigen is an example of a method based on detec-
tion of circulating tumour-associated antigens – specific
proteins released to the circulatory system by neoplastic
cells due to their excessive or incorrect expression. Such
antigens first have to saturate immunologic antigen-
processing capacity and then reach detectable and stable
circulating levels, and that occurs only after some time
from neoplastic transformation [16]. Excessive or modi-
fied expression of specific tumour-associated antigens
can also be a source of autoimmunization and antibodies
production [17,18]. Presence of antibodies reactive toTable 4 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antib




Anti-Hsp60 (AU/ml) 104,17 ± 159,89
(mean ± SD)
% of positive results 26%*
(> 90 percentile for control group) p = 0.0075
Anti-Hsp65 (AU/ml) 106,41 ± 217,07
(mean ± SD)
% of positive results 21,5%*
(> 90 percentile for control group) p = 0.0424
*p < 0.05 in group of women with ovarian cancer compared to control group.tumour-associated antigens can be showed in the circu-
lation already at early stages of its development, and
much earlier than circulating antigens [19-21]. Further-
more, antibody stability is much higher than other
serum biomarkers and less susceptible to effects of vari-
ous disturbing agents [19,20,22], thus the tumour-
reactive antibodies seem to be a more useful diagnostic
marker, particularly at early stages of neoplasm develop-
ment, than tumour-derived antigens [13]. Presence of
antibodies against tumour-associated antigens in serum
was already demonstrated in patients with various neo-
plasms [23-25], including ovarian cancer [13,18,26,27].
They were detectable already at early stages of tumour
development and related to its progress, as well as
allowed distinguishing between benign and malignant le-
sions (13). However, comparing to other malignant neo-







n = 44 n = 23
82,94 ± 82,87 77,77 ± 83,41 62,42 ± 33,93
19% 21% 10%
p = 0.1476 p = 0.1535
78,64 ± 85,73 85,32 ± 92,47 56,35 ± 35,57
15% 29%* 10%
p = 0.3972 p = 0.0200
Table 5 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending
on treatment phase and in control group
Phase of antineoplastic treatment Controls
Untreated so far After chemotherapy n = 80
n = 72 n = 77
Anti-Hsp60 (AU/ml) 89,59 ± 89,99 99,91 ± 158,40 62,42 ± 33,93
(mean ± SD)
% of positive results 28%* 19% 10%
(> 90 percentile for control group) p = 0.0041 p = 0.1085
Anti-Hsp65 (AU/ml) 80,31 ± 86,71 109,64 ± 226,24 56,35 ± 35,57
(mean ± SD)
% of positive results 19% 22%* 10%
(> 90 percentile for control group) p = 0.1103 p = 0.0398
*p < 0.05 in group of women with ovarian cancer compared to control group.
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number of studies on antibodies against tumour-associated
antigens in ovarian cancer [21]. It seems then that search-
ing for such specific antibodies and their quantitative
evaluation may be a key for developing better methods
for early diagnosis of that neoplasm.
Recent years have brought many valuable reports on a
significant role of heat shock proteins in development of
malignant processes, also within the ovary. That role
mainly concerns facilitation of malignant transformation,
progression of tumour cell survival and contribution to
development of resistance to anticancer therapy [1].
However, it is still unknown why Hsps are excessively
expressed in tumour cells. Is it caused by an adverse
microenvironment of the tumour itself (defensive cellu-
lar response) or does it result from genetic modifications
related to malignant transformation [28] Neoplastic cells
seem to be resistant to pro-apoptotic signals, and as
Hsps play an important and comprehensive role in
apoptosis processes and at the same time are expressed
excessively in malignant cells, they are a subject of inten-
sive research, both as possible therapeutic targets and as
prognostic and diagnostic markers [2]. It was proved
that excessive expression of various Hsps was related to
bad prognosis and poor response to therapy in various
types of malignant neoplasms, including ovarian cancer
(reviewed in 2). Some Hsps were identified as tumour-
associated antigens recognised by antibodies present in
serum of patients with ovarian cancer [21], and Hsp27,
Hsp70 and Hsp90 expression in tumour tissues was
positively correlated to the clinical stage of disease
(FIGO) [29]. One of Hsps, which role in malignant neo-
plastic processes is relatively poorly known, is Hsp60. It
seems that in case of prostate cancer increased expres-
sion of that protein occurs at an early stage of malignant
phenotype development [30], and in rectal and cervical
cancers these expression levels increase with malignancy[31,32]. The latest studies showed that in ovarian cancer
Hsp60 expression in tumour tissues visibly increased
versus expression in correct ovarian tissues [33] and
high expression of this protein is also related to poorer
prognosis and higher risk of tumour progression [34,35].
Increased levels of anti-Hsp60 antibodies were found in
sera of patients with osteosarcomas [36]. The mean con-
centrations of anti-Hsp60 and anti-Hsp65 antibodies in
our group of patients with ovarian cancer were higher
than in the control group, but that difference did not
reach the statistical significance level. In the group of
patients, however, the values considered as positive oc-
curred significantly more often. A very interesting obser-
vation was made when the group of women with ovarian
cancer was divided depending on the clinical stage of
disease (FIGO I – IV). It showed that at the early stages,
the mean levels of both studied antibodies were signifi-
cantly higher than in healthy women and significantly
higher than at later stages. The same applies to the occur-
rence of positive values, which in the group of patients
at the I stage occurred in as many as 46% of patients,
while in the group of patients at the II stage – in 27%
of patients. This observation may point that antigenic-
ity of the tumour changes during neoplastic process or
the specific tolerance develops to that antigen, and
thus B-cell reactions are weakened. These results indi-
cate usefulness of assessment of anti-Hsp60/65 anti-
body levels as a diagnostic marker especially at early
clinical stages of the disease, when lack of specific
markers in serum and lack of clinical symptoms often
delay diagnosis. Similar observations were also already
made in ovarian cancer for anti-Hsp27 antibodies. In
the patients at the I and the II clinical stage of disease
the ratio of positive results was 62% and 55%, respect-
ively [37]. Contrary, presence of anti-Hsp90 antibodies
is related to later ovarian cancer stages [38]. The mean
anti-Hsp60 and anti-Hsp65 antibodies levels did not varied
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individual histopathological types differed in positive
value ratios.
Recently, a lot is being said about heat shock proteins
involvement in development of tumour resistance to
non-surgical treatment, and resistance to chemotherapy
is one of fundamental problems in treatment of patients
with advanced ovarian cancer. One of proteins suspected
of participation in development of resistance to chemo-
therapeutics is Hsp60. Increased expression of this pro-
tein was correlated to resistance to cisplatin in various
ovarian cancer cell lines [39]. A weak response or even
resistance to chemotherapy in ovarian cancer cells also
results from increased Hsp27 expression [40]. Hsp60,
Hsp27 (and other Hsps) involvement in development of
tumour resistance to chemotherapy may result from sev-
eral mechanisms. As chaperone molecules, they can
have cytoprotective effect also on neoplastic transformed
cells, “repairing” their proteins damaged by cytotoxic ef-
fect of drugs [2] or increasing repair processes in dam-
aged DNA [41,42]. Many authors are of the opinion that
the crucial mechanism is, however, protection of tumour
cells against apoptosis. The studies suggest this may
occur at several stages, through interference with both
internal and external apoptosis pathways [4]. Following
an analysis of our results it seems that administration of
chemotherapy as primary anticancer treatment has no
significant effect on anti-Hsp60 antibodies level. An in-
teresting observation concerns, on the other hand, levels
of anti-Hsp65 antibodies, which mean value in the group
of patients after chemotherapy is significantly higher
than in the control group. Anti-Hsp60 and anti-Hsp65
antibodies are extensively described in the literature as
cross-reacting antibodies [43,44] due to phylogenetic
similarity between forms of these proteins in microor-
ganisms and in mammals. Observations that increased
levels of antibodies against mycobacterial Hsp65 (75%
homologous with human Hsp60) are related to vascular
diseases severity and progress [45,46] resulted in assump-
tions that immunization against heat shock proteins also
affects development and progress of atherosclerosis [47].
As anti-Hsp65 antibodies mediate cytotoxicity against hu-
man endothelial cells through cross-reaction with Hsp60
on their surface, damage of vascular cells could result
from such reactions in vivo [48]. When levels of anti-
Hsp60 and anti-Hsp65 antibodies are assessed simultan-
eously, usually strong correlation is found between their
values [49,50]. In studied by us groups of women that
were either healthy or had ovarian cancer, levels of these
antibodies were also significantly correlated, although the
strength of positive correlation was higher in healthy
women (R = 0.62 vs. R = 0.35). Without excluding the
cross-reactions mentioned, our results may, however, indi-
cate a diverse nature of both antibodies, e.g., the fact thattheir cross-reactiveness is only partial. They can recognise
different parts of the antigen and have different functional
properties. Prohaszka et al. [51] drew similar conclusions
from their research, in which they showed differences be-
tween anti-Hsp60 and anti-Hsp65 in antigen recognition,
complement activation and specificity. Also Handley et al.
[52] observed that anti-Hsp60 antibodies present in serum
of healthy persons and patients with various autoimmune
diseases were competitively inhibited by Hsp60, but only
slightly, or not at all, by mycobacterial Hsp65. Research of
Metzler et al. [53] showed that antibodies in human serum
reacting with human Hsp60 and/or mycobacterial Hsp65
recognised at least three different epitopes in mycobacter-
ial protein. Different functional properties of both anti-
bodies were also proved by research of Birnie et al. [54],
who observed that increased levels of anti-Hsp60 anti-
bodies indicated poor prognosis for patients with acute
chest pain, while antibodies against mycobacterial Hsp65
had no prognostic value. Significantly higher levels of
anti-Hsp65 antibodies in the group of patients with ovar-
ian cancer after chemotherapy, with the mean levels of
anti-Hsp60 antibodies comparable to the control group,
may also indicate that protein antigenicity was modified
by treatment. Possibly post-translational modifications
caused in endogenous Hsp60 by chemotherapy, make it
homologically more similar to its mycobacterial equiva-
lent, while Hsp60 used in the ELISA test is recombinant
protein without these modifications.
There is reactivity and/or cross-reactivity between
anti-Hsps antibodies and exogenous Hsps of bacterial
origin and endogenous host Hsps, including Hsps circu-
lating in plasma, Hsps present inside cells and on their
surface (also neoplastic cells) and Hsps in the extracellu-
lar space. These antibodies may control the inflamma-
tory response either positively or negatively, it seems
however, they can also have various specific functions in
different pathological conditions [7]. Even antibodies
against highly homologous Hsps (like human Hsp60 and
mycobacterial Hsp65) may be cross-reactive only par-
tially and differ by some functional properties. Detailed
knowledge of these differences and properties remains a
challenge for the future, particularly considering Hsps
and anti-Hsps antibodies involvement in carcinogenesis
and neoplasm progression processes, development of
metastases and resistance to treatment. Our data indi-
cates that high serum concentrations of anti-Hsp60/65
antibodies are particularly characteristic for early clinical
stages of ovarian cancer. However, as they can also be
present in healthy persons [55], there is a need to deter-
mine the cut-off value and to learn how to distinguish
between “normality” and disease using sensitive quanti-
tative techniques [7]. The proposed ELISA technique
seems to be such technique. Although diagnostic levels
of anti-Hsp60/65 antibodies have not been precisely
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detection of ovarian cancer, particularly at early clinical
stages. The nature of the anti-Hsp immune response in
malignant transformation and role of autoantibodies in
that process remain to be clarified – is their presence
serves as anticancer defence, and if so, whether they can
be used as new therapeutic strategies in oncology.
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